Novavax has announced that its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated an efficacy of 89.3% in its UK Phase III trial.
The study, conducted in partnership with the UK government’s Vaccines Taskforce, enrolled more than 15,000 participants between 18 and 84 years of age, including 27% over the age of 65.
The analysis is based on 62 cases, of which 56 cases of COVID-19 were observed in the placebo group compared with six cases observed in the NVX-CoV2373 group, resulting in an estimated vaccine efficacy of 89.3%.
The variant strain of the virus first identified in the UK was detected in over 50% of the study’s polymerase chain reaction (PCR)-confirmed symptomatic cases. Based on PCR performed on strains from 56 of the 62 cases, Novavax’s jab was found to have 95.6% efficacy against the original COVID-19 strain, and 85.6% against the UK variant.
The biotech company also announced successful results from its Phase IIb study conducted in South Africa.
NVX-CoV2373 is a protein-based coronavirus vaccine that is stable when refrigerated at 2C to 8C, and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.
Stanley C Erck, President and CEO of Novavax, said: “We have now reported data on our COVID-19 vaccine from Phase I, II, and III trials involving over 20,000 participants. In addition, our PREVENT-19 US and Mexico clinical trial has randomised over 16,000 participants toward our enrollment goal of 30,000.
“NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19, but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants.
“NVX-CoV2373 has the potential to play an important role in solving this global public health crisis. We look forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as quickly as possible.”
Darcy Jimenez
This is a syndicated feed from Pharmafile
